Enzyme replacement therapy for mucopolysaccharidosis VI: Growth and pubertal development in patients treated with recombinant human N-acetylgalactosamine 4-sulfatase

Journal of Pediatric Rehabilitation Medicine

Volumn 3, Issue 2, 2010, Pages 89-100

  Decker, Celeste ^a   Yu, Zi Fan ^b   Giugliani, Roberto ^c   Schwartz, Ida Vanessa D ^c   Guffon, Nathalie ^d   Teles, Elisa Leo ^e   Miranda, M Clara Sá ^f   Wraith, J Edmond ^g   Beck, Michael ^h   Arash, Laila ^h   Scarpa, Maurizio ⁱ   Ketteridge, David ^j   Hopwood, John J ^j   Plecko, Barbara ^k   Steiner, Robert ^l   Whitley, Chester B ^m   Kaplan, Paige ⁿ   Swiedler, Stuart J ^a   Conrad, Susan ^o   Harmatz, Paul ^o  

^a BIOMARIN PHARMACEUTICAL INC   (United States)

^b University of Iowa   (United States)

^c HOSPITAL DE CLÍNICAS DE PORTO ALEGRE   (Brazil)

^d HOSPICES CIVILS DE LYON   (France)

^e Hospital de São Jõo   (Portugal)

^f UNIVERSITY OF PORTO   (Portugal)

^g ROYAL MANCHESTER CHILDREN S HOSPITAL   (United Kingdom)

^h JOHANNES GUTENBERG UNIVERSITY   (Germany)

ⁱ UNIVERSITY OF PADOVA   (Italy)

^j WOMEN S AND CHILDREN S HOSPITAL   (Australia)

^k Universitatsklinik fur Kinder und Jugendheilkunde Graz   (Austria)

^l OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^m UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

ⁿ CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

^o CHILDREN S HOSPITAL OAKLAND RESEARCH INSTITUTE   (United States)

more..

Author keywords

arylsulfatase B; enzyme replacement therapy; glycosaminoglycans; growth; Mucopolysaccharidosis VI; N acetylgalactosamine 4 sulfatase; puberty

Indexed keywords

GALSULFASE; GLYCOSAMINOGLYCAN;

ADULT; ANTHROPOMETRY; ARTICLE; BODY HEIGHT; BODY MASS; CASE REPORT; CHILD GROWTH; CONTROLLED STUDY; CORRELATION ANALYSIS; ENZYME REPLACEMENT; GROWTH DISORDER; GROWTH RATE; HUMAN; MAROTEAUX LAMY SYNDROME; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PUBERTY; SCORING SYSTEM; TREATMENT DURATION; TREATMENT OUTCOME; URINALYSIS;

EID: 77954629021     PISSN: 18745393     EISSN: 18758894     Source Type: Journal    
DOI: 10.3233/PRM-2010-0113     Document Type: Article

References (32)

1. V. Abbassi, Growth and normal puberty, Pediatrics 102(2 Pt 3) (1998), 507-511.
2. B. Buyukgebiz et al., Maroteaux-Lamy syndrome associated with growth hormone deficiency, Journal of Pediatric Endocrinology & Metabolism 8(4) (1995), 305-307.
3. S. Byers et al., Effect of enzyme replacement therapy on bone formation in a feline model of mucopolysaccharidosis type VI, Bone 21(5) (1997), 425-431. (Pubitemid 27485311)
4. L.A. Clarke et al., Long-term efficacy and safety of laronidase in the treatment of mucopolysaccharidosis I, Pediatrics 123(1) (2009), 229-240.
5. D. Concolino et al., Precocious puberty in Sanfilippo IIIA disease: diagnosis and follow-up of two new cases, Eur J Med Genet 51(5) (2008), 466-471.
6. S.Y. Euling et al., Examination of US puberty-timing data from 1940 to 1994 for secular trends: panel findings, Pediatrics 121(Suppl 3) (2008), S172-S191.
7. R. Giugliani, P. Harmatz and J.E. Wraith, Management guidelines for mucopolysaccharidosis VI, Pediatrics 120(2) (2007), 405-418.
8. P. Hamill et al., Physical growth: National Center for Health Statistics percentiles, Am J Clin Nutr 32(3) (1979), 607-629.
9. P. Harmatz et al., Direct comparison of measures of endurance, mobility, and joint function during enzyme-replacement therapy of mucopolysaccharidosis VI (Maroteaux-Lamy syndrome): results after 48 weeks in a phase 2 open-label clinical study of recombinant human N-acetylgalactosamine 4- sulfatase, Pediatrics 115(6) (2005), e681-e689.
10. P. Harmatz et al., Enzyme replacement therapy for mucopolysaccharidosis VI: a phase 3, randomized, double-blind, placebo-controlled, multinational study of recombinant human N-acetylgalactosamine 4-sulfatase (recombinant human arylsulfatase Bor rhASB) and follow-on, open-label extension study, J Pediatr 148(4) (2006), 533-539.
11. P. Harmatz et al., Enzyme replacement therapy in mucopolysaccharidosis VI (Maroteaux-Lamy syndrome), J Pediatr 144(5) (2004), 574-580.
12. P. Harmatz et al., Long-term follow-up of endurance and safety outcomes during enzyme replacement therapy for mucopolysaccharidosis VI: Final results of three clinical studies of recombinant human N-acetylgalactosamine 4-sulfatase, Mol Genet Metab 94(4) (2008), 469-475.
13. Harriet-Lane, The Harriet Lane Handbook: A Manual for Pediatric House Officers. 16 ed, V.L. Gunn and C. Nechyba, eds, 2002, Philadelphia: Mosby.
14. D. Heron et al., Early diagnosis of Maroteaux-Lamy syndrome in two patients with accelerated growth and advanced bone maturation, Eur J Pediatr 163(6) (2004), 323-326.
15. J.E. Hoover-Fong et al., Age-appropriate body mass index in children with achondroplasia: interpretation in relation to indexes of height, Am J Clin Nutr 88(2) (2008), 364-371.
16. J. Karlberg, A biologically-oriented mathematical model (ICP) for human growth, Acta Paediatr Scand Suppl 350 (1989), 70-94.
17. J. Karlberg, On the construction of the infancy-childhoodpuberty growth standard, Acta Paediatr Scand Suppl 356 (1989), 26-37.
18. W.A. Marshall and J.M. Tanner, Variations in pattern of pubertal changes in girls, Arch Dis Child 44(235) (1969), 291-303.
19. W.A. Marshall and J.M. Tanner, Variations in the pattern of pubertal changes in boys, Arch Dis Child 45(239) (1970), 13-23.
20. A.M. Montano et al., Growth charts for patients affected with Morquio A disease, Am J Med Genet A 146A(10) (2008), 1286-1295.
21. J. Nelson and D. Carson, Pituitary function studies in a case of mild Hunter's syndrome (MPS IIB), J Med Genet 26(11) (1989), 731-732.
22. E. Neufeld and J. Muenzer, The Mucopolysaccharidoses Chapter 136, in: Metabolic and Molecular Bases of Inherited Disease, C. Scriver, ed., 2001, McGraw-Hill: New York.
23. L.E. Polgreen et al., Growth and endocrine function in patients with Hurler syndrome after hematopoietic stem cell transplantation, Bone Marrow Transplant 41(12) (2008), 1005-1011.
24. M. Sifuentes et al., Afollow-up study of MPSI patients treated with laronidase enzyme replacement therapy for 6 years, Mol Genet Metab 90(2) (2007), 171-180.
25. C.M. Simonaro et al., Joint and bone disease in mucopolysaccharidoses VI and VII: identification of new therapeutic targets and biomarkers using animal models, Pediatr Res 57(5 Pt 1) (2005), 701-707.
26. C.M. Simonaro et al., Mechanism of glycosaminoglycanmediated bone and joint disease: implications for the mucopolysaccharidoses and other connective tissue diseases, Am J Pathol 172(1) (2008), 112-122.
27. C.M. Simonaro, M.E. Haskins and E.H. Schuchman, Articular chondrocytes from animals with a dermatan sulfate storage disease undergo a high rate of apoptosis and release nitric oxide and inflammatory cytokines: a possible mechanism underlying degenerative joint disease in the mucopolysaccharidoses, Lab Invest 81(9) (2001), 1319-1328.
28. J. Singer and J. Willett, Applied Longitudinal Data Analysis. 2003, Oxford University Press, Oxford.
29. R.D. Stevenson, Use of segmental measures to estimate stature in children with cerebral palsy, Arch Pediatr Adolesc Med 149(6) (1995), 658-662.
30. S.J. Swiedler et al., Threshold effect of urinary glycosaminoglycans and the walk test as indicators of disease progression in a survey of subjects with Mucopolysaccharidosis VI (Maroteaux-Lamy syndrome), Am J Med Genet A 134A(2) (2005), 144-150.
31. J.M. Tanner and P.S. Davies, Clinical longitudinal standards for height and height velocity for North American children, J Pediatr 107(3) (1985), 317-329.
32. S.P.A. Toledo et al., SERUM GROWTH HORMONE LEVELS IN HUNTER SYNDROME, Revista do Hospital das Clinicas da Faculdade de Medicina da Universidade de Sao Paulo 46(1) (1991), 9-13.